Keytruda passes Phase III bladder cancer test

Merck & Co. Inc. (NYSE:MRK) said PD-1 mAb Keytruda pembrolizumab met the co-primary overall survival (OS) endpoint in the Phase III KEYNOTE-045 trial to treat bladder cancer. The pharma stopped the study early on the recommendation of an independent data monitoring committee.

The open-label KEYNOTE-045 evaluated Keytruda vs. investigator's choice of chemotherapy to treat metastatic, locally advanced or unresectable urothelial cancer that recurred or progressed following platinum-based chemotherapy. Merck said it plans to present the data at an upcoming medical meeting. ...